The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” ...

Tough times in the industry are forcing changes in investment and governance that should result in a healthier sector, the ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

Scientists say HHS’ decision to defund mRNA vaccine research will leave the country less prepared for pandemics, and make it ...

The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency ...

The drug, which functions similar to psilocybin, scored positive enough results in a mid-stage study that Reunion is now ...

The oncology patent cliff presents a complex and urgent challenge. As blockbuster therapies approach loss of exclusivity, the ...

A new wave of Alzheimer’s research suggests semaglutide, widely known for diabetes and weight loss, could also slow cognitive ...

The panel’s reinstatement is one of a series of controversial moves made by Robert F. Kennedy Jr. to put vaccines under new ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...